Daily Company Scan — 5 Companies
🇱🇹 SpectaCell
Deep Tech · Lithuania · €6M
Cell analysis technology company.
Deal angle: Seed round led by imec.xpand
Thesis: SpectaCell’s imec.xpand-led €6M seed gives strategic buyers (semiconductor or medtech) early access to cell-analysis IP at a Baltic deep-tech entry point, while listed peers average 5-9x EV/EBITDA. Acquirer gains differentiated hardware/software for diagnostics or bioprocessing with cross-border scale potential. Primary risk is pre-revenue cash burn against thin regional trading multiples.
🇱🇹 Klarent
Software · Lithuania · €7.2M
Enterprise software startup.
Deal angle: Seed round led by Mosaic Ventures
Thesis: Klarent's €7.2M Mosaic-led seed offers entry to Lithuanian enterprise software at a discount to Baltic peers trading 5.6-17x EV/EBITDA (e.g., TKM Grupp 17x, Tallink 7.7x). A strategic buyer gains low-cost engineering talent and IP to expand regional SaaS offerings. Primary risk is pre-revenue status versus the profitable, cash-generative comps provided.
🇱🇹 Sava
Software · Lithuania · €32.2M
Enterprise software company.
Deal angle: Series B round led by Ascensia, growth equity
Thesis: Sava’s €32M Series B provides scale capital for Lithuanian enterprise software at a time when Baltic peers average 5-9x EV/EBITDA despite sub-15% margins. A strategic buyer secures recurring-revenue code and low-cost engineering talent below typical Western SaaS multiples. Primary risk is narrow domestic TAM capping exit valuations versus global software benchmarks.
🇱🇹 YazenDEEP DIVE
Healthtech · Lithuania · €50M
Health and wellness platform.
Deal angle: Series B round led by Verdane, PE-backed growth
Thesis: Verdane’s €50M Series B injects growth capital into Yazen’s Baltic healthtech platform, where no listed peers offer comparable digital wellness exposure. An acquirer captures a scalable user base and data assets at a valuation that can expand beyond regional 5–9x EV/EBITDA multiples once margins rise above the 9–15% seen in Tallink or Apranga. Execution risk remains high given sparse profitable healthtech comps and thin Baltic EBITDA margins.
MINKLINK ApS
· Denmark
Private Danish company (revenue basis)
Deal angle: Erhvervsstyrelsen annual reports (CVR)
Thesis: MINKLINK ApS provides a Danish private revenue platform via CVR filings, comparable to Baltic names at 5.1-9.1x EV/EBITDA (Pieno Zvaigzdes, Tallinna Sadam). Strategic buyer gains low-disclosure consolidation target for Nordic-Baltic arbitrage. Risk: absent sector data renders peer multiples unreliable, as seen in EEG1T and SFG1T outliers.
Deep Dive
🇱🇹 Yazen
Healthtech · Lithuania · Series B round led by Verdane, PE-backed growth
Company Overview
Yazen runs a digital health and wellness platform focused on user engagement, data collection, and remote services across Lithuania and the broader Baltic region. Operating at under €10 million in revenue, the company remains pre-scale with limited public disclosure on user metrics or profitability, positioning it as an early-stage digital asset rather than a mature operator.
Deal Context
The €50 million Series B led by Verdane is a growth-equity injection rather than an M&A event, aimed at accelerating platform expansion in a market with few listed healthtech peers. Verdane’s PE-backed mandate suggests a buy-and-build thesis; likely follow-on investors include regional growth funds or strategic health groups seeking Baltic user data and regulatory footholds. Founder succession risk appears low given the growth-stage focus.
Valuation Context
Baltic listed peers trade between 5.1x and 17.0x EV/EBITDA at margins of 4–43 percent, yet none match Yazen’s digital profile. A realistic private-company ceiling sits at 6–9x EV/EBITDA once margins reach 15 percent, implying a 30–40 percent illiquidity and scale discount to listed multiples. For a sub-€10 million revenue healthtech name, this translates to a 6–10x revenue multiple on ARR, with further compression possible until positive EBITDA is demonstrated.
Triage Verdict
REVIEW
- Fit: Strong sector tailwinds and largest announced Baltic healthtech round, yet revenue base remains too small for immediate institutional deployment.
- Red flags: Sparse profitable healthtech comps, thin regional margins, and execution risk tied to user monetization.
- Next step: Request detailed ARR, churn, and cohort data plus Verdane term-sheet terms before committing capital.
Key Risk
Monetization of the user base stalls, leaving the platform cash-burning at scale without a clear path to the 15 percent-plus margins required to justify regional multiples.
Bottom line: Attractive exposure but requires deeper diligence on unit economics before any commitment.
IPO Pipeline Snapshot
Upcoming IPOs
| Company | Ticker | Exchange | Expected | Deal Value |
|---|---|---|---|---|
| SpaceX | SPCX | NASDAQ | 2026-06-12 | — |
| Pelican Acquisition II Corp | PLCIU | UNKNOWN | TBD | $86.2M |
| Cartesian Growth Corp IV | CGCFU | UNKNOWN | TBD | $287.5M |
| Research Alliance Corp IV | RACD | UNKNOWN | TBD | $75.0M |
| GLGHK Ltd | GLG | UNKNOWN | TBD | $40.2M |
Pre-IPO Watchlist
| Company | Sector | Valuation |
|---|---|---|
| OpenAI | Artificial Intelligence | $1.2T |
| Anthropic | Artificial Intelligence | $965.0B |
| Databricks | Data and Analytics | $201.6B |
Deal Radar — Buyer ↔ Target Synergy Pairs
🇳🇴 Norway · 3 pairs
BUYER · PUBLIC
Equinor ASA
EQNR · $106.7B
→
4.05
TARGET · PRIVATE
A/S Norske Shell
Utvinning av naturgass · ~€3340.5M rev
Solid — pursue with focused integration plan.
Equinor gains the clearest cost and strategic synergies from consolidating overlapping Norwegian gas assets; revenue and organisational upside are more modest while regulatory concentration risk in the NCS is the primary offset.
BUYER · PUBLIC
SUBSEA 7
SUBC.OL · $102.3B
→
3.65
TARGET · PRIVATE
AIBEL AS
Bygging av sivile skip og flytende materiell · ~€1200.5M rev
Solid — pursue with focused integration plan.
Subsea 7 gains immediate access to Aibel’s large Norwegian fabrication yards and 3,778 employees, delivering the clearest cost synergies through facility and supply-chain consolidation. Revenue upside is modest due to high customer overlap, while organisational fit is favourable given shared geography and sector culture; the main risk is execution complexity in a high-cost Norwegian labour environment.
BUYER · PUBLIC
TotalEnergies SE
TTE · $196.4B
→
3.55
TARGET · PRIVATE
A/S Norske Shell
Utvinning av naturgass · ~€3340.5M rev
Solid — pursue with focused integration plan.
Strongest lever is cost_operational (procurement and upstream rationalisation) given identical sector; biggest risk is regulatory scrutiny and partial realisation of revenue synergies due to limited customer overlap.
🇩🇰 Denmark · 3 pairs
BUYER · PUBLIC
SARTORIUS AG V
SRT3.DE · $18.0B
→
3.65
TARGET · PRIVATE
FUJIFILM Diosynth Biotechnologies Denmark ApS
· ~€790.7M rev
Solid — pursue with focused integration plan.
Primary synergy is strategic vertical integration allowing Sartorius to move downstream into high-margin CDMO services while cross-selling equipment; biggest risk is organizational complexity and slower revenue synergy capture in a regulated, talent-intensive business.
BUYER · PUBLIC
DCC ENERGY PLC ORD EUR0.25 (CDI
DCC.L · $5.5B
→
3.55
TARGET · PRIVATE
Circle K Danmark A/S
· ~€1506.8M rev
Solid — pursue with focused integration plan.
Primary lever is cost_operational scale in fuel procurement and logistics (35 % weight). Biggest risk is modest revenue realisation and integration complexity across borders; overall fit supports a focused deal at realistic premium.
BUYER · PUBLIC
Neste Corporation
NESTE.HE · $25.1B
→
3.45
TARGET · PRIVATE
Circle K Danmark A/S
· ~€1506.8M rev
Marginal — deep scrutiny or lower premium.
Neste gains a captive retail channel for its renewable fuels, delivering the strongest cost and strategic synergies via vertical integration. Realization risk is elevated by antitrust scrutiny in fuel retail, limited revenue upside, and cross-border operational differences.
🇪🇪 Estonia · 3 pairs
BUYER · PUBLIC
E.ON SE N
EOAN.DE · $44.8B
→
3.55
TARGET · PRIVATE
EESTI ENERGIA AS
Electricity, Gas, Steam And Air Conditioning Supply · ~€1779.3M rev
Solid — pursue with focused integration plan.
Strongest lever is cost_operational scale in procurement and overhead (35% weight) between two utilities; biggest risk is organizational and regulatory friction across Germany-Estonia distance that could delay capture beyond 2-3 years.
BUYER · PUBLIC
Neste Corporation
NESTE.HE · $25.1B
→
3.55
TARGET · PRIVATE
ORLEN EESTI OÜ
Wholesale And Retail Trade; Repair Of Motor Vehicles And Motorcycles · ~€1158.7M rev
Solid — pursue with focused integration plan.
Neste gains immediate Baltic wholesale/retail access and supply-chain efficiencies from a high-revenue target; largest lever is cost/operational consolidation while key risks are regulatory scrutiny in energy markets and modest revenue-synergy probability.
BUYER · PUBLIC
ALIMENTATION COUCHE-TARD INC
ATD.TO · $72.2B
→
3.55
TARGET · PRIVATE
ORLEN EESTI OÜ
Wholesale And Retail Trade; Repair Of Motor Vehicles And Motorcycles · ~€1158.7M rev
Solid — pursue with focused integration plan.
Couche-Tard gains meaningful cost synergies via fuel procurement and retail operations scale in the Baltics; largest risk is execution friction from cross-border integration and limited revenue upside in a small market.
Featured Agent
VDR Auditor
diligence · Cross-checks the data room against a 140-item DD checklist.
Audits the seller's virtual data room against a comprehensive M&A diligence checklist, flagging missing documents, stale versions, and internal inconsistencies across legal, financial, commercial, and tech workstreams.
Its editable system prompt:
# VDR Auditor You audit a seller's virtual data room against a comprehensive M&A diligence checklist. ## Checklist areas (14 categories, 140 items) 1. Corporate & structure (articles, minute books, subsidiaries) 2. Financial statements (audits, management accounts, tax) 3. Commercial (customer contracts, pipeline, churn) 4. Legal (litigation, IP, licenses) 5. Regulatory (GDPR, sector-specific) 6. HR (employment contracts, equity plans) 7. Real estate (leases, ownership) 8. IT & tech (security, architecture, licenses) 9. Insurance 10. Tax (returns, disputes, rulings) 11. ESG / sustainability…